Personal information

No personal information available

Activities

Collapse all

Employment (1)

Washington University in Saint Louis: Saint Louis, MO, US

2007-07-01 to present (Division of Oncology)
Employment
Source: Self-asserted source
Andrea Wang-Gillam

Education and qualifications (1)

University of Arkansas System: Little Rock, AR, US

MD, PhD
Education
Source: Self-asserted source
Andrea Wang-Gillam

Works (17)

Data from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

2023-10-06 | Preprint
DOI: 10.1158/1078-0432.c.6532836.v3
Contributors: Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner et al.
Source: check_circle
Crossref

Data from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

2023-10-06 | Preprint
DOI: 10.1158/1078-0432.c.6532836
Contributors: Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner et al.
Source: check_circle
Crossref

Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

2023-10-06 | Preprint
DOI: 10.1158/1078-0432.24261190
Contributors: Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner et al.
Source: check_circle
Crossref

Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

2023-10-06 | Preprint
DOI: 10.1158/1078-0432.24261190.v1
Contributors: Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner et al.
Source: check_circle
Crossref

Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

2023-10-06 | Preprint
DOI: 10.1158/1078-0432.24261187.v1
Contributors: Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner et al.
Source: check_circle
Crossref

Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

2023-10-06 | Preprint
DOI: 10.1158/1078-0432.24261187
Contributors: Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner et al.
Source: check_circle
Crossref

Data from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

2023-10-05 | Preprint
DOI: 10.1158/1078-0432.c.6532836.v2
Contributors: Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner et al.
Source: check_circle
Crossref

Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

2023-10-05 | Preprint
DOI: 10.1158/1078-0432.24251112
Contributors: Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner et al.
Source: check_circle
Crossref

Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

2023-10-05 | Preprint
DOI: 10.1158/1078-0432.24251112.v1
Contributors: Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner et al.
Source: check_circle
Crossref

Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

2023-10-05 | Preprint
DOI: 10.1158/1078-0432.24251109.v1
Contributors: Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner et al.
Source: check_circle
Crossref

Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

2023-10-05 | Preprint
DOI: 10.1158/1078-0432.24251109
Contributors: Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner et al.
Source: check_circle
Crossref

Data from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.c.6532836.v1
Contributors: Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner et al.
Source: check_circle
Crossref

Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488924
Contributors: Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner et al.
Source: check_circle
Crossref

Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488924.v1
Contributors: Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner et al.
Source: check_circle
Crossref

Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488921
Contributors: Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner et al.
Source: check_circle
Crossref

Table S2 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

2023-04-01 | Preprint
DOI: 10.1158/1078-0432.22488921.v1
Contributors: Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner et al.
Source: check_circle
Crossref

Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

Clinical Cancer Research
2022-12-15 | Journal article
DOI: 10.1158/1078-0432.CCR-22-0308
Contributors: Andrea Wang-Gillam; Kian-Huat Lim; Robert McWilliams; Rama Suresh; Albert C. Lockhart; Amberly Brown; Marcus Breden; Jad I. Belle; John Herndon; Savannah J. Bogner et al.
Source: check_circle
Crossref
How many people are using ORCID?